Document:

EXHIBIT
10.7

 

EMPLOYMENT
AGREEMENT

 

THIS
AGREEMENT (the “Agreement”) is made this 1st day of January 2015, between Emerald Medical
Applications Ltd., of 1 Emek Ayalon St., Modi’in, Israel (the “Company”), and Lior Wayn of
1 Emek Ayalon St., Modi’in, Israel (the “Executive” and each of the Company and the Executive, a “Party”
and together the “Parties”).

 

WHEREAS,the
Company desires to employ the Executive as the chief executive officer of the Company (“Position”) in accordance
with the terms and conditions of this Agreement; and

 

WHEREAS,
the Executive wishes to be employed by the Company in the Position and has the knowledge, skills, know-how, ability experience
and expertise in order to fulfil his duties in connection with the Position.

 

NOW,
THEREFORE, in consideration of the foregoing premises and the agreements and covenants herein set forth and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties do hereby agree as follows:

 

	1.	Employment

 

1.1
The Executive shall be employed in the Position and will report to the board of directors of the Company (“Board”).

 

1.2
The Executive shall be employed in a full time position. The weekly rest day of the Executive is Saturday.

 

1.3
The regular working days and hours of the Company, during which the Executive will be working, are Sunday through Thursday between
09:00 and 18:00; provided, however, that due to the seniority of the Executive’s position in the Company’s
management requiring high degree of trust and the inability of the Company to supervise the actual working hours of the Executive,
the Work and Rest Hours Law, 5710 – 1951 shall not apply to the relations between the Executive and the Company.

 

1.4
The Executive agrees to devote his full working time and professional attention to the business and affairs of the Company and
to the performance of his duties hereunder and will carry out his job faithfully and devotedly, in accordance with the objectives
of the Company, as they are defined from time to time by the Board. Nothing herein shall prevent the Executive from pursuing other
activities provided such activities do not jeopardize the performance of his duties hereunder.

 

1.5
The Executive shall notify the Company immediately of every matter or transaction in which Executive has a personal interest and/or
which might create a conflict of interest with Executive’s position in the Company.

 

1.6
The Executive shall not publicize or take any action that might result in adverse effect upon the Company’s reputation or
business relationships, including, to the extent applicable, its clients, affiliates, business partners, officers, directors,
owners or Executives.

 

1.7
The Executive represents and warrants to the Company that (i) entering into this Agreement does not result in any default under,
or breach of any other Agreement or obligation to which Executive is a party to or bound by, (ii) the Executive has the requisite
experience, capabilities, time and other resources needed to perform the duties of his employment.

 

Emerald
Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	1

    	 

    

 

	2.	Place
                                         of Employment

 

2.1
The Executive’s regular place of employment shall be in the Company’s offices in Israel or elsewhere in Israel as
otherwise informed by the Company, and may include travel and periods of stay abroad according to the requirements of the work
to be performed for the Company, as determined by the Company from time to time.

 

	3.	Salary

 

3.1
The Company shall pay the Executive a monthly gross salary which, including all of the employer costs and social benefits associated
with such salary (unless otherwise explicitly set forth in this Agreement), shall be equal to a sum of NIS46,000 (the “Salary”),
paid within the first nine days of each calendar month, with respect to work performed during the preceding calendar month, during
the term of the Executive’s employment hereunder. For the avoidance of doubt a copy of the expected pay slip of the Executive
is attached to this Agreement as Exhibit A.

 

3.2
The Company and the Executive shall conduct discussions in good faith regarding increase of the Salary thirty days prior to each
anniversary of this Agreement, such discussions and increase taking into consideration, inter alia, (i) increase in the
scope of business of the Company and its activities and revenues, (ii) increase in the responsibilities and liabilities of the
Executive, (iii) seniority of the Executive with the Company, and (iv) increase of the Israeli consumer price index.

 

3.3
Notwithstanding anything to the contrary, in the event that the Executive and the Company will decide that the Executive shall
perform his duties not in Israel, the Parties shall discuss in good faith the new terms and conditions of the Executive’s
employment, taking into consideration the country that the Executive is relocated to and a relocation payment to assist the Executive
and his family to relocate. Such new terms and conditions may include, inter alia, health insurance for the Executive and
his family, reimbursements of travel expenses to and from Israel to the Executive and his family, accommodation, participation
in schools tuition, car expenses, etc. For the avoidance of doubt, all of the costs incurred by the Executive and his family due
to the relocation shall be borne solely by the Company.

 

	4.	Additional
                                         Compensation

 

4.1
In addition to the Salary, the Executive shall be entitled to the following bonuses:

 

4.1.1
Revenue Based Bonus - a bonus in an amount equal to 5% of the monthly revenue of the Company during the calendar years ending
December 31, 2015 and December 31, 2016. It is hereby clarified that for the purpose hereof, revenue shall include any income
generated by the Company and/or any of its affiliates including, inter alia, license fees, royalty payments, exclusivity payment,
etc. The Revenue Based Bonus shall be calculated on a monthly basis from the consolidated revenue of the Company, its subsidiaries
and affiliates from time to time. The Revenue Based Bonus shall be paid 4 times a year, on March, June, September and December’s
Salaries; and

 

4.1.2
An additional bonus in an amount equal to 7 month’s salary shall be payable only in the event that Zaxis International,
Inc. (“Zaxis”) shall: (i) raise capital in the amount of at least US$1,150,000 through the sale of equity at
a price of net less that US$0.80 per share; or (ii) warrants are exercised at not less than US$0.80 per share resulting in net
proceeds to Zaxis of at least US$1,150,000.

 

4.2
Except as specifically set forth in this Agreement, any and all taxes and liabilities applicable from time to time in connection
with the Salary, the foregoing bonuses, the Executive benefits provided for hereunder and/or any other payment which the Executive
is entitled to Funder this Agreement, will be borne by the Executive solely and the Company shall be entitled to make any mandatory
deduction and/or withholding.

 

Emerald
Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	2

    	 

    

 

		5.	Benefits

 

5.1
The Executive shall be entitled to the following employee benefits and payments payable with respect to the Salary during his
employment by the Company:

 

5.1.1Pension
Fund/Provident Fund/Managers Insurance.

 

The
Company shall obtain and maintain either Managers Insurance (Bituach Menahalim) Policy, Pension Fund (Keren Pensia) Policy or
Provident Fund Policy (Kupat Gemel) (either one referred as “Policy”), as designated by the Executive no later
than three (3) days following the date hereof, which designation may be modified by the Executive, subject to applicable law,
in a written notice to the Company to be provided within a reasonable time in advance, for the benefit of the Executive in accordance
with applicable law.

 

The
Pension Fund/Provident Fund/Managers Insurance will be calculate and paid from the total gross salary.

 

5.1.2Severance
Payment.

 

The
Executive agrees and acknowledges that payments by the Company to the Policy under Section שגיאה!
מקור ההפניה לא נמצא. above
shall be in lieu of the Company’s statutory obligation to pay severance pay, in accordance with Section 14 of the Severance
Pay Law, 5723-1963 and the approval of the Minister of Labor and Welfare, as amended on March 12, 2001, in the form attached hereto
as Exhibit B (in Hebrew) which has been signed by the Executive concurrently herewith, and is hereby incorporated
into this Agreement and constitutes an integral part hereof.

 

The
Company hereby waives any right to receive any amount paid by the Company on account of the Policy, except in case Executive draws
upon the Policy other than for an “Entitlement Event” (“Eruah Mezake” as defined in Exhibit B),
and provided that (i) the Executive has, of Executive’s own and sole initiative, terminated employment without having given
prior notice as provided in the Notice Period, except as a result of a termination due to circumstances beyond the Executive’s
control, or (ii) the employment is terminated as a result of circumstances under which according to applicable law and/or employment
agreement and/or judicial decision the Executive is not entitled to the full amount of severance pay that would otherwise be payable
under the Severance Pay Law, 5723-1963, in such case those portions of the Policy constituting the Company’s severance payment
contributions, should be refunded to the Company.

 

Upon
the termination of the Executive’s employment, the Company shall release the Policy and transfer it into the name of the
Executive, subject to, and without derogating from, the above provisions.

 

5.1.3Sick
Leave.

 

The
Executive shall be entitled to sick leave in accordance with applicable law, provided, however, that the Executive
shall be entitled to receive full payment for sick leave from the first such day of sick leave.

 

5.1.4Annual
Leave

 

The
Executive shall be entitled to annual leave in accordance with the provisions applicable Israel law.

 

Emerald
Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	3

    	 

    

 

5.1.5Expense
Reimbursement.

 

The
Executive shall be entitled to receive reimbursement for actual business expenses arising out of travel, lodging, meals and entertainment
in connection with the performance of duties hereunder, provided Executive submits proper documentation.

 

In
addition, the Executive is entitled to receive reimbursement of up to NIS1,000 per month for ironing and dry cleaning, communication
expenses, meals, entertainment, etc. against submittal of proper documentation.

 

5.1.6Company
Car

 

In
addition to the Salary, the Executive will shall be entitled to receive a Company car for work related use only, subject to the
Company’s policies as in effect from time to time and as communicated to the Executive. All maintenance expenses, gasoline
expenses and applicable road tolls shall be borne by the Company. The Executive shall be responsible for any and all expenses
or fines arising out of the Executive’s use of the Company car.

 

For
the avoidance of doubt, any tax implications arising from any of the foregoing shall be borne solely by the Company (Gilum) in
addition to the Salary.

 

5.1.7Advanced
Study Fund.

 

The
Company shall contribute to an advanced study fund (Keren Hishtalmut) on the Executive’s behalf an amount equal to 2.5%
of the Salary (which shall be deducted from the Executive’s gross Salary and paid to the advanced study fund), and on behalf
of the Company, 7.5% of the Salary.

 

5.1.8Recuperation
Payment (“Dmei Havraah”).

 

The
Executive shall be entitled to recuperation payments in accordance with applicable law and extension orders. The recuperation
payments shall be made at such times as determined by the Company in accordance with the Company’s policy in effect from
time to time, subject to applicable law and extension orders.

 

5.1.9Mobile
device.

 

The
Executive shall be provided with a cellular smartphone and a cellular line with internet connection by the Company. All expenses
in connection with the cellular smartphone and the cellular line shall be borne by the Company.

 

5.1.10Memberships.

 

The
Company shall bear all reasonable expenses incurred by the Executive relating to membership in any professional organization,
social network, and other profession or career related memberships and expenses.

 

5.1.11Others

 

The
Employee will receive a computer for the work needs.

 

The
employee is committed to take care and keep the computer from any damages.

 

Emerald
Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	4

    	 

    

 

If
the Employee will leave the Company (in any cases), he shell allows to buy the computer – in the 1st year, under a payment
of 50% of the official price (as per ZAP), 25% at the 2nd year and 1% from the 3rd year and on.

 

		6.	Electronic
                                         Mail Box

 

6.1
The Company will provide the Executive with an electronic mail box (“Email”) for the Executive’s use
in connection with his employment by the Company. The Email is intended for work related use only, and is and shall remain the
exclusive property of the Company, as well as any messages, information or documentation contained therein. The Executive may
use Executive’s own private electronic mail account for personal communication.

 

6.2
The Company may inspect the Email from time to time, as well as access, read, copy or erase messages and other information and
documentation contained therein without prior notice.

 

		7.	Intellectual
                                         Property Assignment and Confidentiality

 

7.1
The Executive is aware that in the course of performance of this Agreement, the Executive will have access to and be entrusted
with Confidential Information (as defined in Exhibit C) in respect of the Company and its affiliates and their respective
dealings, transactions, affairs, customers or clients.

 

7.2
In addition, the Parties foresee that in the course of performance of this Agreement, the Executive will have access to and be
entrusted with Confidential Information in respect of the Company and its affiliates and their respective dealings, transactions,
affairs, customers or clients, and that the Executive may make, develop, discover or create any technology in the course of fulfilling
his/her obligations pursuant to this Agreement, and agree that in this respect, the Executive has a special obligation to further
the interests of the Company. In furtherance of the foregoing, the Executive, on or prior to the date hereof, has executed the
Intellectual Property Assignment and Confidentiality Agreement, attached hereto as Exhibit C, which is hereby
incorporated into this Agreement and constitutes an integral part hereof. For the avoidance of doubt, this Section 6 shall survive
the termination of this Agreement for whatever reason.

 

7.3
The Executive acknowledges that the disclosure of the content of this Agreement to any third party, including any other employees,
officers or other representatives of the Company, is reasonably likely to cause the Company severe damages. Therefore, the Executive
agrees to keep this Agreement in confidence and not disclose its content to any Person.

 

		8.	Non-competition,
                                         Non-solicitation

 

8.1
Subject to applicable law, the Executive will not, during the Term (as defined below) and for the period of two (2) years following
the termination of this Agreement (“Restricted Period”), without the prior written consent of the Board, on
the Executive’s own behalf or on behalf of any Person (or as manager, agent, consultant or employee of any Person), either
alone or jointly with others, directly or indirectly, carry on or be engaged by any means in any activity or business, which shall
be similar to or in competition with the Business carried on by the Company on the relevant date during the Term or, with respect
to any action taken following the termination of this Agreement, on the date of termination of this Agreement perform development
activities, or develop technology, similar to the technology developed by or at the direction of the Company and in competition
with the Company.

 

Emerald
Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	5

    	 

    

 

8.2
For the avoidance of doubt, the stipulations set forth in this Non-competition provision do not apply to investments in shares
and/or securities in any company traded on a recognized stock exchange, provided that, without the prior written consent of the
Board, the Executive, on the Executive’s own behalf or on behalf of any Person (or as manager, agent, consultant or employee
of any Person), either alone or jointly with others, directly or indirectly, shall acquire shares, with the exception of the acquisition
of shares in a Company traded on a recognized stock exchange, not exceeding 5% (calculated on a fully diluted basis), in a Company
that is engaged in a business that is the same or similar to the Business of the Company or is in regular business contact with
the Company.

 

8.3
The Executive shall report to the Board if he becomes aware that a close relative of the Executive (which shall include the Executive’s
spouse, parents, children, grandchildren and siblings, including adoptive relationships and relationships through marriage, or
any other relative of Executive that shares the Executive’s home) has become an equity holder, a director or an officer
of a Person, engaged in a business that is the same or similar to the Business of the Company or is in regular business contact
with the Company.

 

8.4
Subject to applicable law, Executive shall not, during the Restricted Period, without the prior written consent of the Board,
in connection with the carrying on of any business similar to or competing with the Business carried on by the Company on the
relevant date during the Term or, with respect to any action taken following the termination of this Agreement, on the date of
termination of this Agreement, on the Executive’s own behalf or on behalf of any Person (or as manager, agent, consultant
or employee of any Person), either alone or jointly with others, directly or indirectly, (i) seek to procure orders from or conduct
business with any Person, who has at any time during the period of two (2) years immediately preceding the relevant date, conducted
business with or been a customer or client of the Company and with whom the Executive (in his capacity as representative or Executive
of the Company) has had business dealings during the Term, or (ii) endeavor to entice away from the Company any employee or any
service provider of the Company, who has at any time during the period of two (2) years immediately preceding the relevant date,
been employed or engaged by the Company. Provided, however, that nothing herein shall prohibit (i) the seeking or procuring of
orders or the conduct of any business not relating or similar to the Business, (ii) any general solicitation not directed specifically
at the Company’s employees of service providers or (iii) any discussions with or employment of any person who approached
the Executive on his own initiative.

 

8.5
The Executive acknowledges that the restrictions set under this Non-competition and Non-solicitation provision are fair and reasonable,
and essential for protection of the Company’s business, the Company’s proprietary rights and other legitimate interests
of the Company, in view of the nature of the business in which the Company is engaged and obligations it has undertaken.

 

8.6
Executive further acknowledges that the above restrictions are customarily complied with by persons situated in a similar position,
correspond with fair dealing requirements and are adequate in light of the Executive’s usage of the Company’s resources
during Executive’s employment hereunder and participation in the Company’s development activities. In addition, such
restrictions are fully compensated for by the Salary, employee benefits and options granted hereunder, in the amount consisting
of 15% of the Salary and of employee benefits (“Special Compensation”), are not likely to have a material adverse
effect upon Executive’s professional position and promotion opportunities during the Restricted Period.

 

8.7
Executive further acknowledges that this Non-competition and Non-solicitation provision is material to the Company in light of
its obligations and nature of activity, that the Company would not have entered into this Agreement without such undertaking by
the Executive and that the Company shall be entitled to seek, in addition to any other remedies applicable, special performance
and return of the special compensation.

 

Emerald
                                         Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	6

    	 

    

 

8.8
Notwithstanding anything contained herein, if any restriction under this Non-competition provision should be held by a court of
competent jurisdiction to be unenforceable under applicable law to its fullest scope, then the restrictions hereunder shall be
interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and intention
of the restrictions, as determined by such court of competent jurisdiction. For the avoidance of doubt, this Section שגיאה!
מקור ההפניה לא נמצא. shall
survive the termination of this Agreement for whatever reason.

 

		9.	Term
                                         and Termination

 

9.1This
Agreement and the Executive’s employment hereunder shall be in effect as of the date first set above and until terminated
in accordance with the provisions of this Agreement.

 

9.2At
any time after the date of this Agreement, either the Company or the Executive may terminate this Agreement on at least one hundred
and eighty days (180) days advance notice (the “Notice Period”). It is hereby clarified that during the first
90 days of the notice period the Executive shall be required, at the sole discretion of the Company, to attend his position in,
and provide services to the Company, whereas, during the second half of the Notice period the Executive shall be entitled to receive
all of the rights under this Agreement but shall not be required to provide any services to the Company.

 

9.3
The Company shall have the right, at its sole discretion, to ask the Executive to cease working or to continue to work during
all or part of the Notice Period. The Executive will cooperate with the Company to ensure an orderly transfer of responsibilities
and know-how to the Executive’s substitute and/or the Board.

 

9.4
The Company may terminate the Executive’s employment for Cause upon delivering a notice with immediate effect, without obligation
for any severance payment. For purposes of this Agreement, termination for “Cause” shall mean and include:
(i) breach of any undertaking relating to confidentiality, non-competition, non-solicitation or intellectual property towards
the Company; (ii) severe breach of discipline, including any refusal to carry out a directive of the Board, which directive is
capable of being lawfully performed, (iii) breach of fiduciary duty towards the Company; and (iv) any cause which allows the Company
to terminate the Agreement without obligation to pay severance payment in accordance with applicable law.

 

9.5
Promptly upon request by the Company, and in any event immediately upon termination of this Agreement, the Executive shall hand
over to the Company (i) all work related documents (without retaining any copies to Executive) in whatever form and irrespective
of whether prepared by Executive or not, as well as documents that have otherwise come to Executive’s possession following
her employment by the Company, and (ii) all other property of the Company. Executive shall assist the Company with due transition
of the Executive’s know-how and responsibilities to the Executive’s substitute and/or and Supervisor.

 

		10.	General

 

10.1This
Agreement is personal and the terms and conditions of the employment shall be conclusively as set forth herein, and the provisions
of any collective agreement, collective arrangement or other custom of any kind shall not apply as far as not mandatory upon the
Parties. The Executive may not assign this Agreement or any of its terms, conditions, obligations or rights herein to any person
and must perform personally all of the undertakings by him herein.

 

10.2
This Agreement is the entire agreement between the parties with respect to the subject matter hereof, supersedes all prior understandings,
agreements and discussions between them, oral or written, and is for the sole benefit of the Parties.

 

Emerald
                                         Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	7

    	 

    

 

10.3
Any amendment or modification of this Agreement shall be made by writing only and signed by both Parties. No waiver by either
party hereto of any of the requirements imposed by this Agreement on, or any breach of any condition or provision of this Agreement
to be performed by, the other party shall be deemed a waiver of a similar or dissimilar requirement, provision or condition of
this Agreement at the same or any prior or subsequent time. Any such waiver shall be express and in writing, and there shall be
no waiver by conduct. Pursuit by either party of any available remedy, either in law or equity, or any action of any kind, does
not constitute waiver of any other remedy or action. Such remedies are cumulative and not exclusive.

 

10.4
If any provision of this Agreement shall be held invalid, illegal or unenforceable in any jurisdiction, the validity, legality
and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired, and the parties
undertake to implement all efforts which are necessary, desirable and sufficient to amend, supplement or substitute all and any
such invalid, illegal or unenforceable provisions with enforceable and valid provisions which would produce as nearly as may be
possible the result previously intended by the parties without renegotiation of any material terms and conditions stipulated herein.

 

10.5
All notices, consents, approvals, agreements, authorizations, acceptances, rejections and waivers under this Agreement must be
in writing and shall be deemed given when: (i) delivered by hand or private, prepaid courier service to the person specified for
the receiving Party at the address specified above; or (ii) mailed to that addressee at that address by a recognized express mail
carrier with package tracking capability or certified mail, return receipt requested, with postage fully prepaid; or (iii) transmitted
by facsimile. A notice by facsimile shall be deemed given, subject to electronic confirmation of delivery, on the date of receipt
if a business day, or on the following business day if received on a day that is not a business day. Each Party may change the
address or person for notification upon 10 days’ notice to the other Party. The initial notification information is as set
forth above.

 

10.6
This Agreement and the rights and obligations arising from it shall be governed by and construed in accordance with the laws of
the State of Israel. The competent courts located in Tel Aviv, Israel, shall have sole jurisdiction regarding all matters arising
from the matters herein or from the employment relations between the Parties.

 

10.7
No term of this Agreement shall survive expiry or termination of this Agreement unless expressly provided.

 

10.8
This Agreement is for the sole benefit of the Parties and their permitted assigns and each such Party intends that this Agreement
shall not benefit, or create any right or cause of action in or on behalf of, any Person other than the Parties, their permitted
assigns.

 

10.9
This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together
shall be deemed to be one and the same instrument. Signed counterparts of this Agreement may be delivered by facsimile and by
scanned .pdf image.

 

10.10
Certain capitalized terms defined in Exhibit D shall have the respective meanings ascribed to them therein.

 

[Signature
page to follow]

 

Emerald
                                         Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	8

    	 

    

 

IN
WITNESS WHEREOF, the parties have duly executed this Agreement on the day and year set forth above.

 

	 	 	 
	Company	 	Lior
    Wayn

 

Emerald
Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	9

    	 

    

 

EXHIBIT
A

 

[Sample
of Pay Slip]

 

Emerald
                                         Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	10

    	 

    

 

EXHIBIT
B

 

Emerald
Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	11

    	 

    

 

EXHIBIT
C

 

INTELLECTUAL
PROPERTY ASSIGNMENT AND CONFIDENTIALITY AGREEMENT

 

THIS
INTELLECTUAL PROPERTY ASSIGNMENT AND CONFIDENTIALITY AGREEMENT (this “Agreement”) is made as of 1 January 2015
(the “Effective Date”) by and between Emerald Medical Applications Ltd. (together with any current or
future subsidiary, the “Company”) and Lior Wayn (the “Executive”).

 

I
wish to enter into this Agreement, effective as of the Effective Date and agree that this Agreement shall constitute a material
part of the consideration for my employment with the Company, and in consideration of the mutual promises and agreements contained
herein and in my employment agreement with the Company, and other good and valuable consideration, the receipt and sufficiency
of which I hereby acknowledge, I agree as follows:

 

		1.	Intellectual
                                         Property

 

A.
Assignment of Inventions. As between the Company and myself, I agree that all right, title, and interest in and to any
and all ideas, copyrightable material, notes, records, data, formulas, source and object code, drawings, designs, inventions (whether
patentable or not), improvements, developments, discoveries and trade secrets conceived, discovered, authored, invented, developed
or reduced to practice by me, solely or in collaboration with others, during the period of time I am employed by the Company (including
during my off-duty hours), or with the use of Company’s equipment, supplies, facilities, or Company Confidential Information,
and any copyrights, patents, trade secrets, know-how, mask work rights or other intellectual property rights relating to the foregoing
(collectively, “Inventions”), are the sole property of the Company. I also agree to promptly make full written
disclosure to the Company of any Inventions, and to deliver and assign and do hereby irrevocably assign fully to the Company the
entire right, title, and interest throughout the world in the Inventions, including all copyright registrations, patent applications
(including, but not limited to, provisional applications, non-provisional applications, PCT applications, and national stage applications)
relating thereto, and all divisions, continuations, continuations-in-part, reissues, and reexaminations thereof, and all rights
of priority under International Conventions and any related Letters Patent, which may hereafter be granted or filed in any country,
all extensions, renewals and reissues thereof. I agree that this assignment includes a present conveyance to the Company of ownership
of Inventions and rights of priority under International Conventions that are not yet in existence. I further acknowledge that
all original works of authorship that are made by me (solely or jointly with others) within the scope of and during the period
of my employment with the Company and are protectable by copyright are “works created by employees” as these terms
are defined in the Israeli Copyright Act, 2007, and are the sole property of the Company. I understand and agree that the decision
whether or not to commercialize or market any Inventions is within the Company’s sole discretion and for the Company’s
sole benefit, and that no royalty or other consideration will be due to me as a result of the Company’s efforts to market,
commercialize, license, or sell, or any such Inventions. I hereby irrevocably waive any claims and any rights in respect of the
Inventions assigned or to be assigned to the Company under or by virtue of this Agreement. I acknowledge that 10% of my consideration
is paid as special supplementary compensation in consideration for my Inventions created, conceived, discovered, authored, invented
and/or developed during the period of time I am employed by the Company (including during my off-duty hours), or with the use
of Company’s equipment, supplies, facilities, or Company’s Inventions (the “Special Invention Compensation”).
I warrant and represent that the Special Invention Compensation constitutes a real, appropriate and full consideration to any
prejudice I may suffer in connection with my Inventions.

 

I
hereby irrevocably waive any past or future claims for compensation or royalties in connection with the Inventions under this
Agreement, including, without limitation, any right to future payments in connection with the commercialization of IP under Section
134 of the Israeli Patents Law and any right to receive compensation in connection with “Service Inventions” under
Section 134 of the Israeli Patent Law of 1967, or any other similar provision under any applicable law of any applicable jurisdiction.
I shall indemnify and hold the Company harmless against any claims or demands (including all legal costs), submitted by me, on
my behalf and/or by any other third party (including the Israeli tax authorities) against the Company or any of its affiliates
in respect of the above.

 

Emerald
Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	12

    	 

    

 

B.Pre-Existing
Materials. I have attached hereto as Schedule 1, a list describing all inventions, discoveries, original works of authorship,
developments, improvements, trade secrets and other proprietary information or intellectual property rights owned by me or in
which I have an interest prior to, or separate from, my employment with the Company, and which relate to the Company’s proposed
business, products, or research and development (“Prior Inventions”); or, if no such list is attached, I represent
and warrant that there are no such Prior Inventions. Furthermore, I represent and warrant that if any Prior Inventions are included
on Schedule 1, they will not materially affect my ability to perform all obligations under this Agreement. I will inform
the Company in writing before incorporating such Prior Inventions into any Invention or otherwise utilizing such Prior Invention
in the course of my employment with the Company, and the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable,
transferable worldwide license (with the right to grant and authorize sublicenses) to make, have made, use, import, offer for
sale, sell, reproduce, distribute, modify, adapt, prepare derivative works of, display, perform, and otherwise exploit such Prior
Inventions, without restriction, including, without limitation, as part of or in connection with such Invention, and to practice
any method related thereto. I will not incorporate any invention, improvement, development, concept, discovery, work of authorship
or other proprietary information owned by any third party into any Invention without the Company’s prior written permission.

 

C.Moral
Rights. Any assignment to the Company of Inventions includes all rights of attribution, paternity, integrity, modification,
disclosure and withdrawal, and any other rights throughout the world that may be known as or referred to as “moral rights,”
“artist’s rights,” “droit moral,” or the like (collectively, “Moral Rights”).
To the extent that Moral Rights cannot be assigned under applicable law, I hereby acknowledge that all Inventions were made as
“works created by employee” conceived, discovered, authored, invented, developed or reduced to practice by me, in
accordance with the Company’s specific instructions, directions and interests for the sole benefit and use of the Company.
Furthermore, I hereby waive and agree not to enforce any and all Moral Rights, including, without limitation, any limitation on
subsequent modification, to the extent permitted under applicable law.

 

D.Maintenance
of Records. I agree to keep and maintain adequate, current, accurate, and authentic written records of all Inventions made
by me (solely or jointly with others) during the term of my employment with the Company. The records may be in the form of notes,
sketches, drawings, electronic files, emails, reports, or any other format that may be specified by the Company. As between Company
and myself, the records are and will be available to and remain the sole personal property of the Company at all times and the
Company shall enjoy the benefits attributed to all such personal property. I also agree to assign and do hereby irrevocably assign
fully to the Company the entire right, title, and interest throughout the world in the written records of all Inventions made
by me (solely or jointly with others) during the term of my employment with the Company. I agree that this assignment includes
a present conveyance to the Company of ownership of the written records of all Inventions, rights of reference thereto, and rights
of priority under International Conventions that are not yet in existence.

 

E.Further
Assurances. I agree to assist the Company, or its designee, at the Company’s expense, in every reasonable way to secure
the Company’s rights in the Inventions, the written records of all Inventions, the rights of reference thereto, and the
rights of priority under International Conventions in any and all countries, including the disclosure to the Company of all pertinent
information and data with respect thereto, the execution of all applications, specifications, oaths, declarations, assignments,
and all other instruments that the Company shall deem proper or necessary in order to apply for, register, obtain, maintain, defend,
and enforce such rights, and in order to deliver, assign and convey to the Company, its successors, assigns, and nominees the
sole and exclusive rights, title, and interest in and to all Inventions, and testifying in a suit or other proceeding relating
to such Inventions, the written records of all Inventions, the rights of reference thereto, and the rights of priority under International
Conventions. I further agree that my obligations under this Section 1.E shall continue after the termination of this Agreement.

 

Emerald
                                         Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	13

    	 

    

 

F.Attorney-in-Fact.
I agree that, if the Company is unable because of my unavailability, unwillingness to participate, mental or physical incapacity,
or for any other reason to secure my signature with respect to any Inventions, the written records of all Inventions, the rights
of reference thereto, and the rights of priority under International Conventions including, without limitation, for the purpose
of applying for or pursuing any application for any United States or foreign patents or mask work or copyright registrations seeking
to protect the same, then I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as
my agent and attorney-in-fact, to act for and on my behalf to execute and file any papers and oaths, or declarations and to do
all other lawfully permitted acts with respect to such Inventions, the written records of all Inventions, the rights of reference
thereto, and the rights of priority under International Conventions so as to acquire protection for such property and/or further
the prosecution and issuance of patents, copyright and mask work registrations with the same legal force and effect as if executed
by me. This power of attorney shall be deemed coupled with an interest, and shall be irrevocable.

 

		2.	Confidentiality

 

A.Confidential
Information. I am aware that the Company possesses valuable information which has commercial value to the Company,
and that in the course of my employment with the Company, I had or will have access to and be entrusted with technical or business
information (and documentation) of the Company, its Affiliates, clients, customers, suppliers (including contractors) and other
third parties doing business with the Company, whether disclosed to, accessed by or otherwise learned by the Company, including:
(i) all information marked as confidential (or with words of similar meaning); (ii) information that is received from a third-party
under conditions of confidentiality; (iii) all information relating to the products, formulations, specifications, Inventions,
manufacturing processes and business affairs of the Company; (iv) anything developed by reference to the information described
in this definition and any notes, analysis summaries and similar documents prepared in connection therewith; (v) “inside
information,” including any material, non-public, price-sensitive corporate or market information relating to the Company,
its Affiliates, clients, customers, suppliers (including contractors) and other third parties doing business with the Company,
that is acquired in connection with the development of products by the Company for any third party, and (vi) certain health and/or
medical information of individuals using the Company’s services (the “Confidential Information”).

 

B.Confidentiality.
I shall keep all Confidential Information in strict confidence and shall not (except in the proper course of my duties), during
or at any time after the employment and for as long as this Agreement requires, including Section E below, disclose to any person
or otherwise make use of (and shall use my reasonable best endeavors to prevent the publication or disclosure of) any Confidential
Information except in connection with my employment with the Company where sharing the information is needed for me to perform
my duties.

 

C.Surrender
of Confidential Information. All notes, memoranda, documents and/or other written Confidential Information (including in electronic
form) concerning the business, Inventions, operations and affairs of the Company, or any of its or their suppliers, agents, distributors
or customers, which shall be acquired, received or made by me during the course of the employment, shall be the property of the
respective entity and shall be surrendered by me to that entity at the termination of the employment, or at the request of the
Company’s chief executive officer, at any time during the course of the employment.

 

D.Exceptions.
This clause 2 shall not apply to information: (i) that is on the Effective Date, or has subsequently come into the public domain
otherwise than by the breach by me of this Agreement or any other obligation of confidentiality by which I am bound contractually,
by law and/or regulation of any form and nature; or (ii) disclosed as mandatorily required by law or regulation, legal process,
judicial order, or other governmental order, or stock exchange regulations.

 

Emerald
                                         Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	14

    	 

    

 

E.Confidential
Information of Third Parties. I will not disclose to the Company, or induce the Company to use, any confidential information
belonging to others for which I am not authorized to share with Company. I will not directly or indirectly use any other party’s
confidential information in connection with my employment with the Company, unless authorized by the other party. I will honor
any and all legal obligations I have to previous employers or other persons or companies with respect to such parties’ confidential
information.

 

F.Confidentiality
Obligations Survive. My obligations hereunder shall survive for three (3) years following any termination or expiration of
my employment with the Company, or this Agreement, provided, that confidentiality obligations with respect to Confidential Information
constituting trade secrets shall continue for as long as such Confidential Information shall be eligible for trade secret protection
under applicable law.

 

G.Breach
of Confidentiality. I hereby acknowledge that a breach of an obligation under this clause 2 shall contradict the nature of
the special trust and relationship of loyalty between the Company and me, the fair and proper business practices, the duty of
good faith and fairness between the Company and me, shall harm the Company, and shall constitute a material breach of this Agreement
and the trade secrets, Confidential Information, and other privileged interests of the Company. The Company shall be entitled
to seek specific performance to enforce my obligations in this Agreement.

 

H.Medical
Information and Privacy. Without derogating form the foregoing, I am aware that I might be exposed to certain health and/or
medical information of individuals, subject to various privacy and security requirements of different jurisdictions, including
(but not limited to) Israeli legislation and U.S legislation, such as the Health Insurance Portability and Accountability Act
of 1996 and the Health Information Technology for Economic & Clinical Health Act and Reinvestment Act of 2009 (“HIPAA”),
all of which are deemed Confidential Information. I am aware that disclosure of such medical Confidential Information is likely
to cause grave personal, financial and other damages to the Company and to individuals to whom such information belongs, and anything
to the contrary herein notwithstanding, such medical and/or health related Confidential Information must be kept in strict confidence,
may not be copied or removed from the premises of the Company and may not be disclosed at any time to any person without prior
written instruction by the Company. The provisions of this Section H shall remain in force and effect perpetually during the term
of this Agreement and following its termination for any reason whatsoever.

 

		3.	Miscellaneous

 

A.Validity.
If any provision of this Agreement is held invalid by a court of competent jurisdiction, the remaining provisions will nonetheless
be enforceable according to their terms. Further, if any provision is held to be overbroad as written that provision should be
considered to be amended to narrow its application to the extent necessary to make the provision enforceable according to applicable
law and enforced as amended.

 

[Signature
page to follow]

 

Emerald
                                         Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	15

    	 

    

 

I
HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. NO
PROMISES OR REPRESENTIONS HAVE BEEN MADE TO ME IN ORDER TO INDUCE ME TO SIGN THIS AGREEMENT. I SIGN THIS AGREEMENT VOLUNTARILY
AND FREELY.

 

	/s/: Lior Wayn	 
	Name:	LIOR
    WAYN	 
	Date:	01/01/2015	 

 

Accepted
and agreed:

 

	/s/:
    Lior Wayn	 
	 	 
	EMERALD
    MEDICAL APPLICATIONS LTD.	 
	 	 
	Name:
    Lior Wayn	 
	Date:
    01/01/2015	 

 

Emerald
Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	16

    	 

    

 

 

Schedule
1

 

Pre-Existing
Inventions

 

None

 

Emerald
                                         Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	17

    	 

    

 

EXHIBIT
D

 

Certain
Definitions

 

	“Business”	means
    the business conducted by the Company from time to time.
	 	 
	“Person”	means
    any entity, corporation, company, joint stock company, partnership, limited liability company, trust, organization, individual
    (including personal representatives, executors and heirs or a deceased individual), trustee, receiver or liquidator, or governmental
    or any other regulatory agency.
	 	 
	“Technology”	means
    all Israeli and non-Israeli: (i) patents and applications therefor, including all continuations, continuations-in-part, divisions,
    extensions, provisionals, re-examinations, reissues and renewals thereof; (ii) trademarks, service marks, trade dress, trade
    names, taglines, brand names, logos, symbols, corporate names and all other indicia of origin, all registrations and applications
    for all of the foregoing, including all extensions, modifications and renewals thereof and all goodwill related thereto; (iii)
    published and unpublished works of authorship (including software in both source code and object code), mask works and moral
    rights, copyrights therein and thereto, and all registrations and applications for all of the foregoing, including all extensions,
    renewals, restorations and reversions thereof; (iv) trade secrets, know-how, inventions, discoveries, ideas (whether patentable
    or not), technical information, processes, procedures, databases, designs, confidential business information, specifications
    and other proprietary information and rights; (v) domain names and Internet addresses; and (vi) all other intellectual property
    or proprietary rights and claims or causes of action arising out of or related to any infringement, misappropriation or other
    violation of any of the foregoing, including rights to recover for past, present and future violations thereof.

 

Emerald
                                         Medical Applications Ltd.

 

1 Emek Ayalon St. Modiin 7170634, Israel

 

    	18EXHIBIT
10.8

 

SERVICES
AGREEMENT

 

THIS
ZAXIS GILBOA SERVICES AGREEMENT (the “Agreement”) is dated as of March 22, 2015, between ZAXIS INTERNATIONAL
INC., a Delaware corporation (the “Company”) and Oded Gilboa (the “Provider”). The Company
and The provider are sometimes referred to collectively, as the “Parties” and individually, as a “Party.”

 

WHEREAS,
the Company desires to engage the provider to perform the following CFO, Accounting, Book and record keeping duties:

 

	 	1.	Maintaining books
    and records and bookkeeping
	 	2.	Preparation of
    quarterly and annual SEC reports
	 	3.	Maintaining investor
    agreement and legal agreement,
	 	4.	Payments processing
    and bank relationships
	 	5.	Responding to
    auditors inquires
	 	6.	Interfacing with
    Attorney on all legal and compliance matters
	 	7.	Servicing investors
    with Share certificates issuance and processing broker.
	 	8.	Attending company
    meetings and performing special projects as needed

 

NOW
THEREFOR, the Parties agree as follows:

 

1.Services:The
provider agrees perform the above listed services (the “Services”). It is understood and agreed by the Parties that
the provider shall devote no more than 128 hours per month, or 4 working days per week in the performance of the Services.

 

2.Compensation:

 

	 	2.1	In consideration
    for Accounting, Book and record keeping services as listed above to be provided by the provider, the Company shall pay Galor
    Kedma Ltd., an entity controlled by the provider, for the term of the agreement and for the initial two months of service
    $2,000 (two thousand dollars) per month after initial two months and until end of term (as defined below) USD $3,000 (three
    thousand dollars) per month.
	 	 	 
	 	2.1	In consideration
    for CFO services to be rendered and performed by the Provider during the term and in consideration of the Provider having
    entered into this Agreement, the Company shall issue to the Provider 125,000 shares of common stock (the “equity compensation”).
    Equity compensation will be in restricted shares of common stock of the Company, vesting over 4 quarters from date of this
    agreement in equal installments, to be issued and registered to the name of Galor Kedma Ltd. No shares will be sold by the
    Provider that are not vested as per this agreement.

 

	 	2.1.1	The Provider
    understands that the Company, a “shell company” as that term is defined in Rule 405 promulgated by the SEC under
    the Act and further understands and agrees that the certificate(s) evidencing the Share compensation will not be issued to
    the Provider until the pending reverse split of the Company’s common stock on a one-for-four (1:4) basis (the “Reverse
    Stock Split”) is cleared by the SEC and is approved by FINRA.
	 	 	 
	 	2.1.2	The Provider
    acknowledges his/its understanding that the issuance of the Equity compensation, with registration under is intended to be
    exempt from registration under Section 4(2) of the Act and Regulation S or Regulation D, as the case may be, promulgated by
    the SEC under the Act. In furtherance thereof, the Provider hereby represents and warrants to the Corporation that he/it is
    an “accredited investor” as that term is defined in Rule 501 of the General Rules and Regulations under the Act
    by reason of Rule 501(a)(3). The Provider is acquiring the Equity compensation for his/its own account, as principal and not
    as a nominee or agent, for investment purposes only, and not with a view to, or for, resale, distribution or fractionalization
    thereof, either in whole or in part, and no other person has any direct or indirect beneficial interest in such Equity compensation
    or any portion thereof. The Provider has or will have: (a) the financial ability to bear the economic risk of his/its investment;
    (b) has adequate means for providing for his/its current needs and contingencies; and (c) has no need for liquidity with respect
    to his investment in the Corporation. The Provider has such knowledge and experience in financial and business matters as
    to be capable of evaluating the merits and risks of the prospective investment in the Equity compensation. The Provider has
    been provided an opportunity for a reasonable period of time prior to the date hereof to obtain additional information concerning
    the Corporation and any other information he/it has requested regarding the Corporation.

 

    	1

    	 

    

 

	 	2.2.2	The Provider
    understands that any Equity compensation he/it receives will not be registered under the Act or the securities laws of any
    state thereof, nor is the Corporation contractually obligated to register the Equity compensation under the Act. As a result,
    the Provider understands and agrees further that the Equity compensation must be held and may not be transferred until and
    unless the Equity compensation are registered under the Act and the securities laws of any other jurisdiction or an exemption
    from registration under the Act and any applicable laws is available. The Provider understands any certificate(s) evidencing
    the Equity compensation will bear an appropriate restrictive legend reflecting that the Equity compensation have not been
    registered under the Act and the securities laws of any other jurisdiction and setting out or referring to the restrictions
    on the transferability and resale of the Equity compensation will be placed on the books of the Corporation, the records of
    the transfer agent for the Corporation’s common stock and all other documents with respect to the Equity compensation.
	 	 	 
	 	2.2.3	Notwithstanding
    the forgoing, the Provider understands that the Corporation plans or may plan to file a registration statement on Form S-1
    with the SEC for the purpose of, among other things, registering the Corporation’s securities on behalf of selling shareholders
    and others (the “Registration Statement”) and, in the event that the Corporation determines to file a Registration
    Statement, it will register the Provider’s Equity compensation issued or to be issued under this Agreement, subject
    to the following terms, which shall be applicable to the Provider’s Equity compensation as well as those of the other
    selling shareholders: (a) one-third (1/3) of the Equity compensation will be available for resale immediately on and after
    the effective date of the Registration Statement (the “Effective Date”); (b) an additional one-third (1/3) of
    the Equity compensation will be available for resale on and after a date six (6) months from the Effective Date; and (c) the
    remaining one-third (1/3) of the Equity compensation will be available for resale on and after a date twelve (12) months from
    the Effective Date.
	 	 	 
	 	2.2.4	The Provider
    acknowledges and agrees that, in the event that any taxes of any kind whatsoever may be, or become, due under the laws of
    the United States, the State of Israel or any other jurisdiction (collectively, the “Tax Liabilities”) as a result
    of the compensation paid or is payable to the Provider under this Agreement, whether in the form of cash, equity otherwise,
    the Provider shall be solely and totally responsible for any and all Tax Liabilities, none of which shall be the responsibility
    of the Corporation.

 

3.Expenses:
The Company agrees to reimburse The provider for all reasonable expenses incurred in the performance of the Services under this
Agreement, provided that The provider submit on a monthly basis copies of all invoices of such expense disbursements by The provider.

 

4.Right
of Termination:

 

	 	(a)	This agreement
    shall be of an initial term of two (2) years starting with January 15, 2015 (the ‘term’). If a party wishes
    to terminate before end of term such terminating party shall provide notice of the same to the non-terminating party at least
    30 days prior to the end of the term. If no such notice is provided, this agreement shall continue in form for additional
    one year terms until so terminated.
	 	 	 
	 	(b)	This Agreement
    may be terminated by the Company upon happing of any of the following events:
	 	 	 
	 	a.	Whenever the
    company and The provider shall mutually agree to terminate in writing
	 	 	 
	 	b.	The company may
    at any time terminate this agreement by written notice and discharge the provider upon a finding by the Company’s Board
    of Directors of good cause (as defined below) for such termination, whereupon the company’s obligation to pay all compensation
    shall cease as of the date for termination.

 

As
used herein, termination for good cause shall mean termination of this agreement by reason of (i) material breach of this Agreement
by The provider (ii) intentional nonperformance or mis-performance of such duties, or refusal to abide by or comply with the reasonable
directives of his superior officers, or the Corporation’s policies and procedures; (iii) Executive’s gross negligence
in the performance of his material duties under this Agreement; (iv) Executive’s willful dishonesty, fraud or misconduct
with respect to the business or affairs of the Corporation, that in the reasonable judgment of the Board of Directors materially
and adversely affects the Corporation; or (v) provider conviction of a felony or other crime involving moral turpitude. (vi) the
commission of any act in direct or indirect competition with or materially detrimental to the best interests of Corporation that
is in breach of Executive s fiduciary duties of care, loyalty and good faith to Corporation. All notices will set forth in reasonable
detail the facts and circumstances claimed to provide a basis for a finding of good cause allowing to terminate the agreement.

 

    	2

    	 

    

 

	 	c.	Should this agreement
    be terminated for any other reason or should then the provider shall have the right to elect to be terminated for non-cause
    and in either case, The provider shall be paid all sums due and becoming due for a period of six (6) months from he date of
    such termination.

 

The
provider may terminate this agreement and the rights and obligations hereunder upon thirty (30) days prior written notice to the
other Party.

 

5.Miscellaneous:

 

(i)Entire
Agreement:This Agreement and the related agreements and exhibits constitute the entire agreement between the Parties
hereto with respect to the subject matter hereof;

 

(ii)Amendment:This
Agreement may not be amended or modified in any respect, except by the mutual written agreement of the Parties hereto;

 

(iii)
Attorney’s Fees and costs: in the event of a dispute arising between the parties hereto, and said dispute becomes
the subject of arbitration and/or litigation relating to the rights, duties and obligation arising out of this agreement the prevailing
party in such action shall be entitled to recover all applicable costs of said action, including but not limited to, reasonable
attorney’s fees.

 

(iv)Counterparts:This
Agreement may be executed in any number of counterparts and by the separate Parties hereto in separate counterparts, each of which
shall be deemed to be one and the same instrument; and

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the day and year first above written.

 

	The
    provider	 	ZAXIS
    INTERNATIONAL INC.
	 	 	 
	/s/: Oded
    Gilboa	 	/s/:
    Liron Carmel
	Oded Gilboa
    	 	Liron Carmel,
    CEO
	Galor Kedma
    Ltd. 	 	 

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]